BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

Dermatologica Sinica, published by Wolters Kluwer Medknow Publications, is an esteemed open-access journal in the field of dermatology that has been disseminating critical research since its inception in 2005. With an E-ISSN of 2223-330X and an ISSN of 1027-8117, this journal presents a platform for researchers, clinicians, and students to share cutting-edge findings and advancements in dermatological science. As of 2023, it proudly ranks in the Q2 category of dermatology journals and holds a notable position at rank #62 out of 142 in the Scopus Medicine - Dermatology category, placing it in the 56th percentile for impact. The journal transitioned to an open-access model in 2016, enhancing accessibility and visibility for groundbreaking studies worldwide. With a commitment to fostering innovation in the dermatological community, Dermatologica Sinica aims to advance the understanding and treatment of skin diseases while encouraging scholarly dialogue among practitioners and researchers across the globe.

EXPERIMENTAL DERMATOLOGY, published by WILEY, is a leading journal in the fields of Biochemistry and Dermatology, with impressive rankings including Q1 status in both categories as of 2023. With its ISSN 0906-6705 and E-ISSN 1600-0625, the journal offers a reputable platform for disseminating cutting-edge research and insights into skin biology and related health issues. As a pivotal resource for professionals, researchers, and students alike, EXPERIMENTAL DERMATOLOGY includes a broad scope of topics, fostering a deeper understanding of dermatological conditions and enhancing new therapeutic strategies. The journal’s distinguished performance is highlighted by its Scopus rankings, which place it at the 91st percentile in Medicine-Dermatology and the 65th in Biochemistry. While not an open-access publication, the journal remains committed to ensuring the accessibility of crucial developments within the dermatological community worldwide, facilitating the advancement of both clinical practice and academic inquiry.

The Journal of Dermatology, published by Wiley, is a premier academic journal dedicated to advancing the field of dermatology, with its esteemed reputation reflected in its Q1 ranking in Dermatology and a remarkable Q2 ranking in Miscellaneous Medicine as of 2023. Since its inception in 1974, the journal has become a vital resource for researchers, clinicians, and students alike, covering pioneering studies and cutting-edge advancements in skin health and disease. With a Scopus rank of #32 out of 142 in the Dermatology category, placing it in the 77th percentile, the journal underscores its commitment to fostering knowledge and innovation within the dermatological community. Although the journal operates under a subscription model, it remains an essential platform for disseminating impactful research that shapes clinical practice and enhances patient care. For anyone invested in dermatological sciences, Journal of Dermatology serves as a key publication where critical insights and developments are regularly showcased.

The British Journal of Dermatology, published by Oxford University Press, stands as a premier platform for advancing the field of dermatological research and clinical practice since its inception in 1892. With a strong commitment to disseminating high-quality research, this esteemed journal is currently ranked in the Q1 category for both Dermatology and Miscellaneous Medicine in 2023, reflecting its influential position in the academic landscape. As the leading journal in its field, it enjoys a robust Scopus ranking of #1 out of 142 in dermatology, placing it in the 99th percentile globally. The journal covers a wide scope of subjects pertinent to dermatology, including clinical trials, treatment innovations, and epidemiological studies, making it an essential resource for researchers, healthcare professionals, and students alike. Although it is not an open-access publication, it ensures a broad reach through institutional subscriptions, fostering knowledge exchange across the global dermatological community. Based in the heart of the United Kingdom, the British Journal of Dermatology continues to play a crucial role in shaping the future of skin health and disease management.

CLINICAL AND EXPERIMENTAL DERMATOLOGY is a prominent journal in the field of dermatology, published by Oxford University Press. With an ISSN of 0307-6938 and an E-ISSN of 1365-2230, this journal has been a vital resource for researchers and practitioners since its inception in 1976. Recognized as a Q2 journal within the category of dermatology for 2023, it holds a respectable position, ranking #54 among 142 journals in this discipline, placing it in the 62nd percentile on Scopus. The journal is dedicated to publishing high-quality research that spans clinical and experimental aspects of dermatological science, making it an essential source of knowledge for advancing understanding and treatment of skin disorders. Although it operates on a traditional subscription model without open access options, its contributions to the field are significant, influencing both clinical practices and academic research. Researchers, clinicians, and students alike will find vital insights and contemporary themes presented in its pages, supporting ongoing education and innovation in dermatology.

CONTACT DERMATITIS, published by WILEY, is a leading international journal focused on the vital field of dermatology, particularly examining the diagnosis, treatment, and management of contact dermatitis and related skin conditions. With origins dating back to 1975 and a planned convergence period extending to 2024, this esteemed journal serves as a crucial resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge in dermatological practices. In the latest rankings, it has achieved a commendable Q2 classification in Dermatology and Q3 classification in Immunology and Allergy for 2023, underscoring its significance within these dynamic fields. Moreover, it holds a notable ranking of #29/142 in Medicine & Dermatology and #130/233 in Medicine & Immunology and Allergy according to Scopus metrics, placing it in the top tier of scholarly publications. While the journal operates on a subscription basis, its comprehensive reviews, original articles, and insightful research findings are invaluable for pushing the boundaries of current dermatological and immunological knowledge. By fostering a deeper understanding of the complexities of skin reactions and their implications, CONTACT DERMATITIS plays a vital role in connecting research with clinical practice, making it an essential read for anyone engaged in the field.

SKIN RESEARCH AND TECHNOLOGY, a distinguished publication by Wiley, stands at the forefront of dermatological science, emphasizing innovative research and technological advances in skin health. With an ISSN of 0909-752X and an E-ISSN of 1600-0846, this journal serves as a vital platform for researchers and professionals to present their findings and engage in discussions surrounding skin biology, clinical practices, and therapeutic technologies. As evidenced by its respectable Q2 ranking in the dermatology category for 2023 and a Q3 status in miscellaneous medicine, the journal attracts a broad readership and contributes significantly to the field. Housed in the United Kingdom with publications spanning from 1995 to 2024, SKIN RESEARCH AND TECHNOLOGY continues to foster innovation and knowledge dissemination in skin-related research. While its Access options are not open, the impact of the journal remains prominent, appealing to academic professionals and students eager to explore emerging trends and advancements in dermatological studies.

Dermatology Research and Practice is a premier open access journal published by HINDAWI LTD, dedicated to advancing the field of dermatology since its establishment in 2009. With a respectable impact factor and a ranking of #42 out of 142 in the Scopus Medicine - Dermatology category, the journal stands in the 70th percentile, reflecting its influence and relevance in contemporary dermatological research. Based in Egypt, it provides a platform for groundbreaking studies that shape clinical practice and policy worldwide. The journal covers a wide range of topics within dermatology, including but not limited to clinical research, epidemiology, and patient care, making it an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding and contribute to the field. Emphasizing open access, Dermatology Research and Practice ensures that vital research findings are readily available to the global community, fostering collaboration and innovation in dermatology.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.